Incyte’s JAK1 inhibitor itacitinib has failed a key trial in graft-versus-host disease (GVHD), marking another setback for a company in need of more drug successes. The pivotal Phase 3 GRAVITAS ...

Belumosudil – a Rho-associated protein kinase-2 (ROCK2) inhibitor that reduces immune mediators like IL-17 and IL-23 – would be a first-in-class therapy for GVHD if approved by the FDA, says ...

The global market for Graft Versus Host Disease (GvHD) Treatment was estimated at US$2.9 Billion in 2024 and is projected to reach US$4.5 Billion by 2030, growing at a CAGR of 7.3% from 2024 to 2030.

Imagine this scenario: you need an urgent blood transfusion, and your brother is present. Thinking it’s safest, you use his ...

John Levine, M.D., a graft-versus-host-disease expert at the Icahn School of Medicine at Mount Sinai in New York, makes a ...

Amandeep Salhotra, MD, discusses data from the phase 3 Precision-T trial of Orca-T in patients with advanced hematologic malignancies.

Graft vs. host disease (GVHD) can occur after a stem cell transplant from a donor. Transplants replace unhealthy cells with healthy blood-forming cells, which can treat some cancers. GVHD happens ...

Pharmaceutical Investments in Novel Immunosuppressive Drugs and Biologics Have Expanded Treatment ChoicesDublin, May 13, 2025 (GLOBE NEWSWIRE) -- The "Graft Versus Host Disease (GvHD) Treatment - ...